Digoxin, propranolol, and atrioventricular reentrant tachycardia in the Wolff-Parkinson-White syndrome.
In 22 patients with atrioventricular reentrant tachycardia incorporating a retrogradely conducting accessory pathway, electrophysiologic studies were done before and after oral digoxin, 1.25 mg, and propranolol, 160 to 240 mg, each given in 4 divided doses at 6-hour intervals. Before digoxin and propranolol, all 22 patients had induction of sustained tachycardia. After the medication six patients lost the ability to induce atrial echo and one lost the ability to sustain tachycardia due to an increased retrograde accessory pathway or atrial refractoriness or both. Six patients lost the ability to induce or sustain tachycardia due to increased atrioventricular nodal refractoriness. In the remaining nine patients with inducible sustained tachycardia, cycle lengths of tachycardia were prolonged. These findings suggest that combined use of oral digoxin and propranolol is useful in selected patients with atrioventricular reentrant tachycardia.
D000293:Adolescent; D000328:Adult; D000368:Aged; D004077:Digoxin / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects; D006334:Heart Function Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use*; D013610:Tachycardia / Q000188:drug therapy*; D014927:Wolff-Parkinson-White Syndrome / Q000188:drug therapy*
D004077:Digoxin; D011433:Propranolol